Safety, efficacy, and pharmacokinetics of navitoclax (ABT-263) in combination with irinotecan: results of an open-label, phase 1 study. (Q53324308)

13 May 2018

title

Safety, efficacy, and pharmacokinetics of navitoclax (ABT-263) in combination with irinotecan: results of an open-label, phase 1 study. (English)

1 reference

13 May 2018

1 reference

1 reference

Anthony W Tolcher

1

1 reference

13 May 2018

Patricia LoRusso

2

1 reference

13 May 2018

Jennifer Arzt

3

1 reference

13 May 2018

Todd A Busman

4

1 reference

13 May 2018

Guinan Lian

5

1 reference

13 May 2018

Niki S Rudersdorf

6

1 reference

13 May 2018

Carol Ann Vanderwal

7

1 reference

13 May 2018

Jeffrey F Waring

8

1 reference

13 May 2018

Jianning Yang

9

1 reference

13 May 2018

Kyle D Holen

10

1 reference

13 May 2018

Lee S Rosen

11

1 reference

13 May 2018

publication date

1 October 2015

1 reference

13 May 2018

Cancer Chemotherapy and Pharmacology

published in

1 reference

13 May 2018

volume

76

1 reference

13 May 2018

issue

5

1 reference

13 May 2018

page(s)

1041-1049

1 reference

13 May 2018

Targeting the B-cell lymphoma/leukemia 2 family in cancer

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2882-9

Mitochondrial signaling in cell death via the Bcl-2 family

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2882-9

Bcl-x(L) and Myeloid cell leukaemia-1 contribute to apoptosis resistance of colorectal cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2882-9

Merkel cell carcinoma dependence on bcl-2 family members for survival.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2882-9

Bcl-2 expression in rituximab refractory cutaneous B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2882-9

Apoptosis initiated when BH3 ligands engage multiple Bcl-2 homologs, not Bax or Bak

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2882-9

ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2882-9

Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2882-9

Differential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2882-9

Discovery of an orally bioavailable small molecule inhibitor of prosurvival B-cell lymphoma 2 proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2882-9

The Bcl-2/Bcl-X(L)/Bcl-w inhibitor, navitoclax, enhances the activity of chemotherapeutic agents in vitro and in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2882-9

Navitoclax (ABT-263) accelerates apoptosis during drug-induced mitotic arrest by antagonizing Bcl-xL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2882-9

The Bcl-2 inhibitor ABT-263 enhances the response of multiple chemotherapeutic regimens in hematologic tumors in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2882-9

Phase I study of Navitoclax (ABT-263), a novel Bcl-2 family inhibitor, in patients with small-cell lung cancer and other solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2882-9

Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2882-9

Phase II study of single-agent navitoclax (ABT-263) and biomarker correlates in patients with relapsed small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2882-9

Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2882-9

Navitoclax (ABT-263) and bendamustine ± rituximab induce enhanced killing of non-Hodgkin's lymphoma tumours in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2882-9

A phase I clinical trial of navitoclax, a targeted high-affinity Bcl-2 family inhibitor, in combination with gemcitabine in patients with solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2882-9

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2882-9

10.1007/S00280-015-2882-9

21 January 2018

Identifiers

DOI

1 reference

13 May 2018

1 reference

13 May 2018